Lupus Science & Medicine

Papers
(The H4-Index of Lupus Science & Medicine is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field212
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol57
Genetic load in incomplete lupus erythematosus46
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease43
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children42
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus42
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases41
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort39
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus37
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms36
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE35
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine32
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus31
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus28
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial28
Mesenchymal stem cells improve ovarian function by suppressing fibrosis through CTGF/FAK signalling in systemic lupus erythematosus27
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials26
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit24
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance24
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory23
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response23
Canadian workplace experiences of systemic lupus erythematosus (SLE)21
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort21
0.061511039733887